TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

Company Overview

TriSalus Life Sciences is a clinical-stage medical technology company focused on the development and commercialization of thermoconductive agent systems designed to enhance the precision and efficacy of localized tumor ablation and targeted drug delivery. The company’s proprietary formulations are activated by external energy sources—such as radiofrequency, microwave or laser—to generate focused thermal effects within cancerous and precancerous lesions. By combining heat-sensitive liposomal compounds with image-guided energy devices, TriSalus aims to improve outcomes in the treatment of solid tumors while minimizing damage to surrounding healthy tissue.

Since its founding in 2019, TriSalus has advanced multiple product candidates through preclinical studies and early clinical trials. The company acquired the exclusive rights to a heat-activated liposomal chemotherapy agent and holds an investigational device exemption for its thermal ablation platform. TriSalus’s lead programs include a Phase III trial for a thermally activated doxorubicin formulation and continued development of an adjunctive agent designed to augment ablation zones during interventional oncology procedures. These efforts build on research collaborations with academic medical centers and strategic alliances aimed at accelerating regulatory approvals.

Headquartered in Houston, Texas, TriSalus serves a network of cancer centers and interventional radiology practices across the United States. The company’s products are being evaluated in diverse indications, including primary liver cancer, metastatic disease and soft tissue sarcomas. With plans to expand into international markets, TriSalus is forging partnerships with distributors and clinical cooperatives to support multi-center trials and eventual commercial launch.

Leadership at TriSalus comprises seasoned professionals from biotechnology, medical device and pharmaceutical sectors. Chief Executive Officer Dr. Stefan Hock brings more than two decades of experience in translational oncology research and corporate development. The executive team includes experts in clinical operations, regulatory affairs and manufacturing scale-up, all working to advance the company’s mission of delivering next-generation tools for minimally invasive cancer treatment.

Key Stats

• Today's Range: $4.85 to $5.11
• 50-Day Range: $4.90 to $5.59
• 52-Week Range: $3.50 to $6.04
• Volume: 39,629 shs
• Average Volume: 52,006 shs
• Market Capitalization: $189.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.75
• Consensus Rating: Buy

TriSalus Life Sciences Stock Analysis - MarketRank™

TriSalus Life Sciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 505th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TriSalus Life Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TriSalus Life Sciences is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TriSalus Life Sciences is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.75% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 266.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TriSalus Life Sciences does not currently pay a dividend.

Dividend Growth

TriSalus Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.75% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 266.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for TriSalus Life Sciences this week, compared to 1 article on an average week.

Search Interest

1 people have searched for TLSI on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TriSalus Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,528.00 in company stock.

Percentage Held by Insiders

27.50% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

TLSI Stock Analysis - Frequently Asked Questions

How have TLSI shares performed this year?

TriSalus Life Sciences' stock was trading at $5.01 at the beginning of the year. Since then, TLSI shares have decreased by 0.2% and is now trading at $5.00.

How were TriSalus Life Sciences' earnings last quarter?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.13. The firm had revenue of $9.17 million for the quarter, compared to the consensus estimate of $9.04 million.
Read the conference call transcript.

How do I buy shares of TriSalus Life Sciences?

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TriSalus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TLSI
• Previous Symbol: NASDAQ:TLSI
• CIK: 1826667
• Web: trisaluslifesci.com
• Phone: 888-321-5212
• Fax: N/A
• Employees: 106
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TriSalus Life Sciences: $10.75
• High Price Target: $12.50
• Low Price Target: $10.00
• Potential Upside/Downside: +115.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.05 million
• Net Margins: -84.67%
• Pretax Margin: -84.65%
• Return on Equity: N/A
• Return on Assets: -111.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.14
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $29.43 million
• Price / Sales: 6.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.83) per share
• Price / Book: -6.02

Miscellaneous

• Outstanding Shares: 37,840,000
• Free Float: 27,433,000
• Market Cap: $189.20 million
• Optionable: Not Optionable
• Beta: 0.50